Breaking News, Promotions & Moves

Owen Murray Tapped as CEO of Combined Bend Bioscience, CoreRx and Societal Entities

Murray brings extensive expertise spanning early product development through commercialization.

Author Image

By: Charlie Sternberg

Associate Editor

QHP Capital has appointed Owen Murray as the new CEO of the combined Bend Bioscience, CoreRx, and Societal entities. Murray joins the company from Aprecia Pharmaceutical, where he served as CEO.   With over 25 years of experience in the pharmaceutical and healthcare industries, Murray brings extensive expertise spanning early product development through commercialization. Prior to his role at Aprecia, he held various senior positions at Cardinal Health, Lundbeck, Ovation Pharmaceuticals, and R...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters